- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
By Joe Mont2016-09-27T12:45:00
At a recent hearing with the CEO of Mylan, the maker of EpiPen, legislators hinted at not only price controls, but an increased scrutiny of executive pay. Joe Mont has more.
2019-07-31T16:35:00Z By Jaclyn Jaeger
Mylan disclosed in a regulatory filing that it has reached a $30 million agreement-in-principle to resolve the SEC’s investigation alleging securities violations for disclosures surrounding EpiPens.
2018-04-06T15:45:00Z By Jaclyn Jaeger
A handful of drug makers have lost their battle with investors who had submitted proposals seeking more information on the potential link between executive compensation packages and rising drug prices.
2017-08-22T12:15:00Z By Joe Mont
Mylan, maker of the EpiPen, has agreed to pay $465 million to settle Department of Justice allegations that it violated the False Claims Act by misclassifying the epinephrine injector as a generic drug to avoid paying Medicaid rebates.
Site powered by Webvision Cloud